Skip to main navigation
  • FibroGen China
  • Newsroom
  • Contact
  • About Us
    • Our Company
    • Our Strategy
    • FibroGen China
    • Executive Team
    • Board of Directors
    • Our Partners
    • Contact Us
  • Focus Areas
    • Our Expertise
    • Anemia
    • Idiopathic Pulmonary Fibrosis
    • Pancreatic Cancer
    • Duchenne Muscular Dystrophy
    • Publications
  • Pipeline
    • R&D Pipeline
    • Roxadustat
    • Pamrevlumab
  • Clinical Trials
    • Our Priorities
    • Roxadustat Trials
    • Pamrevlumab Trials
  • Careers
    • Our Culture
    • Career Opportunities
  • Investors and Media

    Investor Relations

    • Investor Overview
    • Stock Information
    • News Releases
    • Events and Presentations
    • Corporate Governance
    • SEC Filings
    • Financial Information
    • Shareholder Services
    • Investor FAQs
MENU MENU
close x
  • About Us
    • Our Company
    • Our Strategy
    • FibroGen China
    • Executive Team
    • Board of Directors
    • Our Partners
    • Contact Us
  • Focus Areas
    • Our Expertise
    • Anemia
    • Idiopathic Pulmonary Fibrosis
    • Pancreatic Cancer
    • Duchenne Muscular Dystrophy
    • Publications
  • Pipeline
    • R&D Pipeline
    • Roxadustat
    • Pamrevlumab
  • Clinical Trials
    • Our Priorities
    • Roxadustat Trials
    • Pamrevlumab Trials
  • Careers
    • Our Culture
    • Career Opportunities
  • Investors and Media

    Iphone menu

    • Investor Overview
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Documents & Charters
      • Committee Composition
      • Contact the Board
    • SEC Filings
    • Financial Information
      • Form 8937
    • Shareholder Services
      • Contact Investor Relations
      • E-mail Alerts
    • Investor FAQs
  • FibroGen China
  • Newsroom
  • Contact

Investors and Media

Press Releases

Keyword Search

  • February 27, 2023
    FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
  • February 27, 2023
    FibroGen to Present at Cowen’s 43rd Annual Health Care Conference
  • February 17, 2023
    FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
  • February 2, 2023
    FibroGen to Present at SVB Securities Global Biopharma Conference

Investors and Media

  • Investor Overview
  • Stock Information
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • SEC Filings
  • Financial Information
  • Shareholder Services
  • Investor FAQs

FibroGen Inc.

Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor and Media Contact

  • Investors:
    Michael Tung, M.D.
    Corporate Strategy / Investor Relations
    mtung@fibrogen.com

  • Media Inquiries:
    Meichiel Keenan
    Public Affairs
    mkeenan@fibrogen.com

Shareholder Tools

  • Print Page
  • RSS Feeds
  • E-mail Alerts

About Us

  • Our Company
  • Our Strategy
  • FibroGen China
  • Executive Team
  • Board of Directors
  • Our Partners
  • Contact Us

Focus Areas

  • Our Expertise
  • Anemia
  • Idiopathic Pulmonary Fibrosis
  • Pancreatic Cancer
  • Duchenne Muscular Dystrophy
  • Publications

Pipeline

  • R&D Pipeline
  • Roxadustat
  • Pamrevlumab

Clinical Trials

  • Our Priorities
  • Roxadustat Trials
  • Pamrevlumab Trials

Careers

  • Our Culture
  • Career Opportunities

Investors & Media

Investor Relations

  • Investor Overview
  • Stock Information
  • News Releases
  • Events and Presentations
  • Corporate Governance
  • SEC Filings
  • Financial Information
  • Shareholder Services
  • Investor FAQs
  • Terms of Use
  • Privacy Notice
  • About Us
  • Focus Area
  • Pipeline
  • Clinical Trials
  • Investors and Media
  • Terms of Use
  • Privacy Notice
  • © 2023 FibroGen, Inc.
  • 409 Illinois Street, San Francisco, CA 94158